What is the BPC-157 + KPV + TB-500 stack?

This is a 3-peptide anti-inflammation and recovery stack that combines BPC-157 (localized tissue repair and gut healing), KPV (molecular-level anti-inflammation via NF-κB inhibition), and TB-500 (systemic healing and cell migration). It is designed for chronic inflammatory conditions, autoimmune-related tissue damage, and comprehensive recovery where a 2-peptide stack may not provide sufficient coverage.

How is this different from the Wolverine Stack (BPC-157 + TB-500)?

The Wolverine Stack focuses on musculoskeletal injury repair with two peptides. This stack adds KPV, a potent anti-inflammatory peptide derived from alpha-MSH that directly inhibits NF-κB signaling — the master switch of inflammation. The addition of KPV makes this stack significantly more effective for chronic inflammatory conditions, gut inflammation, and autoimmune-related damage where the inflammatory cascade itself is a primary driver of the condition.

Can I take all three peptides at the same time?

Yes. BPC-157 and KPV can be taken together (especially orally for gut-focused protocols), and TB-500 can be injected in the same session using a separate syringe. Do not mix different peptides in the same syringe unless the formulation is specifically designed for it. For SubQ protocols, you can inject all three in one session at different sites.

Should I use oral or injectable for this stack?

It depends on your primary goal. For gut inflammation (IBD, IBS, leaky gut, colitis), oral BPC-157 (500–750 mcg) and oral KPV (200–500 mcg) on an empty stomach are preferred, with TB-500 injected SubQ. For systemic inflammation (joint pain, autoimmune flares, widespread tissue damage), SubQ injection of all three provides better systemic bioavailability. Many users combine both routes: oral BPC-157 and KPV for gut healing plus SubQ TB-500 for systemic coverage.

How long does this stack take to show results?

For acute inflammation, many users report noticeable improvement within 1–2 weeks. Chronic inflammatory conditions and autoimmune-related issues typically require 4–6 weeks before significant progress. Gut healing protocols often show initial improvement in digestive symptoms within 2–3 weeks, with more complete mucosal healing over 6–8 weeks. Full protocol duration is 6–8 weeks, extendable to 12 weeks for chronic conditions.

Is KPV safe to use long-term?

KPV has demonstrated a favorable safety profile in available research. However, as a potent anti-inflammatory that modulates immune signaling, prolonged use (beyond 8–12 weeks) should be monitored for signs of excessive immunosuppression. Take breaks between cycles and assess your response. KPV is not FDA-approved for human use and long-term human safety data is limited.

Can this stack help with IBD or autoimmune gut conditions?

This stack is one of the most popular peptide protocols for inflammatory gut conditions in the research peptide community. BPC-157 has extensive animal data showing gut mucosal protection and healing. KPV has demonstrated anti-inflammatory activity in colitis models by inhibiting NF-κB. TB-500 adds systemic anti-inflammatory support. However, these are research peptides — not FDA-approved treatments. Work with a healthcare provider for inflammatory bowel disease management.

Do I need all three peptides or can I start with two?

You can start with a 2-peptide combination. BPC-157 + KPV (without TB-500) is effective for gut-focused inflammation where systemic healing support is less critical. BPC-157 + TB-500 (the Wolverine Stack, without KPV) is better for musculoskeletal injuries without a significant inflammatory component. The full 3-peptide stack is most beneficial when you need comprehensive coverage: molecular anti-inflammation, localized repair, and systemic healing simultaneously.

How many vials do I need for a full cycle?

For an 8-week cycle with the standard protocol: BPC-157 at 500 mcg daily requires 28 mg total (six 5 mg vials). KPV at 500 mcg daily requires 28 mg total (vial count depends on supplier sizing). TB-500 at 2.5 mg twice weekly for 4 weeks (loading) then once weekly for 4 weeks (maintenance) requires 30 mg total (six 5 mg vials). Budget approximately 86 mg of combined peptide for a complete cycle.

Is this stack banned in sports?

BPC-157 and TB-500 are both prohibited by the World Anti-Doping Agency (WADA) for competitive athletes. KPV is derived from alpha-MSH, and melanocortin peptides fall under WADA prohibited categories. Athletes subject to anti-doping testing should not use this stack.

Can I add other peptides to this stack?

Yes. Common additions include CJC-1295 + Ipamorelin (GH secretagogue stack) for broader tissue recovery and collagen synthesis, or LL-37 for additional antimicrobial support in gut protocols. However, adding more peptides increases complexity and cost. The 3-peptide stack already provides comprehensive inflammatory and healing coverage for most users.

What if I only have gut issues and no musculoskeletal injuries?

For gut-only protocols, the BPC-157 + KPV combination (without TB-500) may be sufficient. Both can be taken orally for direct gut action. However, many chronic gut inflammatory conditions involve systemic inflammation as well, and TB-500's systemic anti-inflammatory and tissue remodeling properties can support overall recovery. If budget allows, the full stack provides more comprehensive support even for gut-focused protocols.

BPC-157 + KPV + TB-500 Stack Guide

The Inflammation & Recovery Protocol — a comprehensive 3-peptide stack combining gut repair, molecular anti-inflammation, and systemic tissue healing for chronic inflammatory conditions and autoimmune support.

Compiled by PeptideWiki Editorial Team

Stack Overview

The BPC-157 + KPV + TB-500 stack is the most comprehensive anti-inflammation and recovery peptide combination available. It pairs BPC-157's localized tissue repair and gut mucosal healing with KPV's potent molecular anti-inflammation (NF-κB inhibition) and TB-500's systemic cell migration and tissue remodeling — addressing inflammation from molecular, local, and systemic levels simultaneously.

Key Characteristics:

3-peptide stack — BPC-157 (Body Protection Compound-157) + KPV (alpha-MSH fragment) + TB-500 (Thymosin Beta-4 fragment)
Primary goal — systemic inflammation reduction, gut healing, tissue repair, autoimmune support, and chronic inflammatory condition management
Triple-mechanism synergy — molecular anti-inflammation (KPV) + localized tissue repair (BPC-157) + systemic healing and cell migration (TB-500)
Experience level — intermediate; recommended for users familiar with at least one of these peptides individually before combining all three
Typical cycle — 6–8 weeks, extendable to 12 weeks for chronic inflammatory conditions
Administration — BPC-157 and KPV can be taken orally (gut focus) or SubQ (systemic); TB-500 subcutaneous injection only

Use our Peptide Dosage Calculator to calculate exact doses for all three peptides based on your vial sizes and reconstitution volumes.

Important: BPC-157, KPV, and TB-500 are not FDA-approved for human use. All three are classified as research peptides. All dosing information in this guide is derived from animal studies and community protocols — not from human clinical trials. Consult a healthcare provider before using any research peptide.

Why This Stack Works

This stack is effective because it attacks inflammation and tissue damage from three fundamentally different angles. Rather than relying on a single mechanism, the combination provides molecular-level, localized, and systemic coverage for comprehensive inflammatory management.

KPV: The Molecular Anti-Inflammatory

NF-κB inhibition: directly suppresses NF-κB signaling, the master transcription factor that drives inflammatory cytokine production (TNF-α, IL-6, IL-1β)
Alpha-MSH fragment: a tripeptide (Lys-Pro-Val) derived from the C-terminal of alpha-melanocyte-stimulating hormone, retaining its anti-inflammatory properties without melanogenic effects
Antimicrobial activity: demonstrates direct antimicrobial properties against common gut pathogens, supporting gut microbiome balance
Mucosal protection: reduces inflammatory infiltration in intestinal mucosa, with demonstrated benefit in colitis models

BPC-157: The Local Repair Agent

Angiogenesis: upregulates VEGF (vascular endothelial growth factor), promoting new blood vessel formation to deliver nutrients and oxygen to damaged tissue
Gut mucosal healing: protects and repairs gastrointestinal mucosa, with demonstrated benefit in ulcer, fistula, and inflammatory bowel models
Growth factor expression: increases EGF, FGF, and other factors that stimulate cell proliferation and tissue remodeling
Nitric oxide modulation: interacts with the NO system to regulate blood flow, inflammation, and repair signaling

TB-500: The Systemic Healer

Actin regulation: sequesters G-actin to promote cell migration, allowing repair cells to reach damaged tissue throughout the body
Systemic anti-inflammation: reduces inflammation throughout the body, creating a favorable healing environment beyond any single injury site
Tissue remodeling: promotes tissue remodeling and reduces scar tissue formation, improving functional recovery
Blood cell production: stimulates new blood cell formation and improves endothelial cell function

The Triple Synergy

KPV suppresses the inflammatory cascade at its molecular root (NF-κB), reducing the production of inflammatory cytokines that perpetuate tissue damage. BPC-157 then creates a favorable local healing environment with new blood vessels, growth factors, and mucosal protection. TB-500 complements both by driving systemic cell migration and tissue remodeling. The result: inflammation is addressed at the source (KPV), damaged tissue is actively repaired (BPC-157), and healing cells are mobilized throughout the body (TB-500).

Evidence note: All three peptides have individual animal research supporting their mechanisms. KPV's NF-κB inhibition is well-documented in cell and animal models. The synergistic benefit of this specific 3-peptide combination is primarily supported by community experience and mechanistic reasoning rather than controlled human trials of the combination.

Individual Peptide Breakdown

Each peptide in this stack has a dedicated dosage guide with complete individual protocols. Here is a summary of each peptide's role in this stack.

BPC-157 (Body Protection Compound-157)

Type: Synthetic pentadecapeptide (15 amino acids)
Origin: Derived from human gastric juice proteins
Role in stack: Localized tissue repair, gut mucosal healing, angiogenesis
Route: SubQ (near injury) or oral (gut focus)
Frequency: Once or twice daily

Full BPC-157 Dosage Guide →

KPV (Alpha-MSH Fragment)

Type: Tripeptide (Lys-Pro-Val, 3 amino acids)
Origin: C-terminal fragment of alpha-melanocyte-stimulating hormone
Role in stack: NF-κB inhibition, molecular anti-inflammation, antimicrobial
Route: SubQ or oral (gut focus)
Frequency: Once daily

Full KPV Dosage Guide →

TB-500 (Thymosin Beta-4 Fragment)

Type: Synthetic peptide fragment of Thymosin Beta-4 (43 amino acids)
Origin: Based on naturally occurring thymic peptide involved in cell migration
Role in stack: Systemic anti-inflammation, cell migration, tissue remodeling
Route: Subcutaneous injection
Frequency: Twice weekly (loading), once weekly (maintenance)

Full TB-500 Dosage Guide →

Dosing Protocol

This stack uses different dosing frequencies for each peptide. BPC-157 and KPV are dosed daily while TB-500 follows a loading/maintenance schedule with less frequent injections.

Standard Protocol (Systemic Focus)

Compound	Dose	Frequency	Route	Notes
BPC-157	250–500 mcg	1–2x daily	SubQ	Consistent daily dosing throughout the entire cycle
KPV	200–500 mcg	Once daily	SubQ	Consistent daily dosing; start at 200 mcg and titrate up
TB-500	2–2.5 mg	Twice weekly (loading)	SubQ	Loading phase: weeks 1–4 to build systemic levels
TB-500	2–2.5 mg	Once weekly (maintenance)	SubQ	Maintenance phase: weeks 5–8 after loading

Gut-Focused Protocol (Oral BPC-157 + KPV)

Compound	Dose	Frequency	Route	Notes
BPC-157	500–750 mcg	Once daily	Oral (empty stomach)	Direct GI mucosal contact; take 30 min before food
KPV	200–500 mcg	Once daily	Oral (empty stomach)	Take with BPC-157 for combined gut action
TB-500	2–2.5 mg	Twice weekly (loading)	SubQ	Systemic anti-inflammatory support; 4-week loading then weekly

Protocol selection: Choose the systemic protocol for widespread inflammation, joint pain, autoimmune flares, and general tissue recovery. Choose the gut-focused protocol for IBD, IBS, leaky gut, colitis, and GI-dominant inflammatory conditions. Some users combine both: oral BPC-157 and KPV in the morning for gut healing, plus SubQ TB-500 twice weekly for systemic support.

Calculate Your Doses

All three peptides are supplied as lyophilized powder and need reconstitution with bacteriostatic water (for injectable use). The dose you draw depends on the concentration after reconstitution.

BPC-157 — 5 mg Vial

Vial size: 5 mg (5,000 mcg)
Bacteriostatic water: 2 mL
Concentration: 5,000 ÷ 2 = 2,500 mcg/mL
250 mcg dose = 0.1 mL = 10 units on insulin syringe
500 mcg dose = 0.2 mL = 20 units on insulin syringe
Doses per vial: 10–20 doses (depending on 500 or 250 mcg)

KPV — 5 mg Vial

Vial size: 5 mg (5,000 mcg)
Bacteriostatic water: 2 mL
Concentration: 5,000 ÷ 2 = 2,500 mcg/mL
500 mcg dose = 0.2 mL = 20 units on insulin syringe
Doses per vial: 10 doses (at 500 mcg)

TB-500 — 5 mg Vial

Vial size: 5 mg (5,000 mcg)
Bacteriostatic water: 1 mL
Concentration: 5,000 ÷ 1 = 5,000 mcg/mL
2.5 mg dose = 0.5 mL = 50 units on insulin syringe
Doses per vial: 2 doses

Skip the Math — Use Our Calculator

Enter your vial size, water volume, and desired dose for each peptide — get instant calculations with zero manual math.

Reconstitution Guide

All three peptides follow the same reconstitution process. Reconstitute each vial separately with bacteriostatic water. If using oral BPC-157 or KPV capsules, reconstitution is not needed for those peptides.

Peptide	Vial Size	Bac Water	Concentration	Standard Dose Draw
BPC-157	5 mg	2 mL	2,500 mcg/mL	10 units (0.1 mL) for 250 mcg
KPV	5 mg	2 mL	2,500 mcg/mL	20 units (0.2 mL) for 500 mcg
TB-500	5 mg	1 mL	5,000 mcg/mL	50 units (0.5 mL) for 2.5 mg

Wash Hands & Prepare Workspace

Wash hands thoroughly. Lay out supplies: peptide vials, bacteriostatic water, insulin syringes, and alcohol swabs on a clean surface.

Swab All Vial Stoppers

Remove plastic caps and swab the rubber stoppers of each peptide vial and the bacteriostatic water vial with alcohol pads. Let air-dry for 10–15 seconds.

Add Water to Each Peptide Vial

Draw the appropriate volume of bacteriostatic water for each vial. Insert needle and direct the stream down the inside glass wall — never squirt directly onto the powder. Release slowly. Reconstitute each vial separately.

Dissolve Gently

Let each vial sit for 1–2 minutes, then gently swirl or roll between palms until fully dissolved. Solution should be clear and colorless. Never shake.

Label & Refrigerate

Write the reconstitution date and concentration on each vial. Store all vials refrigerated at 2–8°C. Use within 28–30 days.

For a detailed visual walkthrough, see our Reconstitution Guide.

Timing & Daily Schedule

BPC-157 and KPV are dosed daily, while TB-500 follows a different schedule. Here is how a typical week looks during the loading phase (weeks 1–4):

Day	BPC-157	KPV	TB-500
Monday	250 mcg AM + 250 mcg PM	500 mcg AM	2.5 mg
Tuesday	250 mcg AM + 250 mcg PM	500 mcg AM	—
Wednesday	250 mcg AM + 250 mcg PM	500 mcg AM	—
Thursday	250 mcg AM + 250 mcg PM	500 mcg AM	2.5 mg
Friday	250 mcg AM + 250 mcg PM	500 mcg AM	—
Saturday	250 mcg AM + 250 mcg PM	500 mcg AM	—
Sunday	250 mcg AM + 250 mcg PM	500 mcg AM	—

Timing Notes

BPC-157: Split doses 8–12 hours apart (e.g., 8 AM and 8 PM). For oral dosing, take on an empty stomach 30 minutes before food.
KPV: Take once daily in the morning. For oral dosing, take with oral BPC-157 on an empty stomach. For SubQ, inject at any convenient time.
TB-500: Can be injected at any time of day. Space injections 3–4 days apart during loading (e.g., Monday/Thursday or Tuesday/Friday).
Same session: All three peptides can be administered in the same session. Use separate syringes for each injectable. No waiting period between injections.
Injection sites: BPC-157 near the injury or abdomen; KPV in the abdomen; TB-500 works systemically from any SubQ site (abdomen is most convenient).

Maintenance phase (weeks 5–8+): BPC-157 and KPV continue at the same daily doses. TB-500 drops to once weekly — pick one consistent day (e.g., every Monday).

Cycling & Duration

This stack is typically run for 6–8 weeks, with the option to extend to 12 weeks for chronic inflammatory conditions. Periodic reassessment is important for longer cycles.

Phase	Duration	BPC-157	KPV	TB-500
Loading	Weeks 1–4	250–500 mcg 1–2x/day	200–500 mcg daily	2–2.5 mg 2x/week
Maintenance	Weeks 5–8	250–500 mcg 1–2x/day	200–500 mcg daily	2–2.5 mg 1x/week
Extended (optional)	Weeks 9–12	250–500 mcg 1–2x/day	200–500 mcg daily	2–2.5 mg 1x/week
Break	2–4 weeks off	None	None	None
Repeat (if needed)	6–8 weeks	Resume full protocol	Resume full protocol	Resume with loading phase

When to Extend to 12 Weeks

Chronic inflammatory bowel conditions: Long-standing IBD, Crohn's-related inflammation, or chronic colitis may require extended duration for meaningful mucosal remodeling
Autoimmune-related tissue damage: When inflammation is driven by autoimmune processes, longer suppression of the inflammatory cascade allows more complete tissue repair
Multiple inflammatory sites: When addressing both gut inflammation and systemic joint/tissue inflammation simultaneously, a longer cycle provides adequate healing time for all affected areas

Why Take a Break?

The break period is particularly important for this stack due to KPV's immune-modulating effects. It serves to: (1) assess healing progress without peptide support, (2) confirm that improvement is structural rather than just symptomatic, (3) allow the immune system to return to baseline signaling, and (4) monitor for any signs of excessive immunosuppression from prolonged KPV use.

Safety, Side Effects & Contraindications

Safety profile: All three peptides — BPC-157, KPV, and TB-500 — have demonstrated favorable safety profiles in animal studies and community use. However, human clinical trial data is extremely limited for all three, and long-term safety of the combination has not been formally evaluated.

Common Side Effects

Injection site redness, soreness, or minor swelling — the most common report for all injectable peptides
Mild skin flushing — more common with KPV due to its alpha-MSH origin; typically transient
Mild nausea — more common with BPC-157, especially oral dosing; usually resolves within days
Transient fatigue or lethargy — occasionally reported
Headache — may occur in the first few days of use
Dizziness or lightheadedness — rare, typically mild and short-lived

Contraindications

Active cancer or history of cancer: BPC-157 promotes angiogenesis and TB-500 promotes cell migration, which could theoretically support tumor growth. Avoid use with active malignancies.
Pregnancy and breastfeeding: No safety data exists for any of these peptides during pregnancy or nursing. Avoid entirely.
Active immunosuppressive therapy: KPV modulates immune signaling. Combining it with immunosuppressive medications may lead to excessive immune dampening. Consult your healthcare provider.
Active infections at injection site: Do not inject through infected, inflamed, or broken skin.
Anticoagulant therapy: BPC-157 interacts with the NO system and may affect platelet function. Consult your healthcare provider if taking blood thinners.

Stack-Specific Safety Notes

No known negative interaction: BPC-157, KPV, and TB-500 have not been shown to interfere with each other. They operate through different mechanisms and pathways.
KPV immunomodulation: KPV's NF-κB inhibition is beneficial for reducing inflammation but may dampen the immune response with prolonged use. Monitor for increased frequency of minor infections during extended cycles.
Increased angiogenic load: Both BPC-157 and TB-500 promote aspects of tissue repair involving vascularization. This reinforces the theoretical concern about use with active cancers.
Separate syringes: Use dedicated syringes for each injectable peptide to avoid any potential compatibility issues in solution.

Regulatory status: BPC-157, KPV, and TB-500 are not FDA-approved for human use. All are classified as research peptides. BPC-157 and TB-500 are prohibited by WADA for competitive athletes. KPV falls under melanocortin peptide restrictions. Regulations vary by jurisdiction — verify your local laws before purchasing.

Common Inflammation Stack Mistakes

Avoid these common errors to get the most out of your BPC-157 + KPV + TB-500 protocol:

Not using the oral route for gut-focused protocols

When targeting gut inflammation (IBD, leaky gut, colitis), oral administration of BPC-157 and KPV delivers the peptides directly to the GI mucosa. SubQ injection provides systemic benefits but misses the direct local action on gut tissue. For gut-focused goals, oral dosing on an empty stomach is essential.

Expecting quick results with chronic inflammation

Chronic inflammatory conditions (autoimmune disorders, long-standing gut inflammation) develop over months or years. Peptides will not reverse this in days. Allow 4–6 weeks minimum for meaningful improvement and complete the full 6–8 week cycle before assessing whether the protocol is working.

Stopping the protocol too early

Symptom improvement after 2–3 weeks does not mean the underlying inflammation is resolved. Inflammatory tissue remodeling takes 6–8 weeks minimum. Stopping early risks relapse and incomplete healing. Complete the full cycle duration.

Using only one or two peptides when the full stack is needed

Each peptide in this stack addresses a different aspect of the inflammatory cascade: KPV targets molecular NF-κB signaling, BPC-157 handles localized tissue repair, and TB-500 provides systemic cell migration and healing. For comprehensive chronic inflammation, all three mechanisms work together. Omitting one leaves a gap in coverage.

Skipping the TB-500 loading phase

TB-500 requires a loading phase (2–2.5 mg twice weekly for 4–6 weeks) to build up systemic levels. Starting at the maintenance dose provides inadequate tissue saturation and delays the systemic anti-inflammatory benefit that complements BPC-157 and KPV.

Mixing all three peptides in the same syringe

Stability and compatibility data for combining reconstituted BPC-157, KPV, and TB-500 in one syringe is not established. Use separate syringes for each peptide to ensure integrity and accurate dosing. For oral peptides, BPC-157 and KPV capsules can be taken together.

Not monitoring for immunosuppression with prolonged KPV use

KPV is a potent anti-inflammatory that modulates immune signaling pathways. Extended use beyond 8–12 weeks without breaks may lead to excessive dampening of the immune response. Watch for increased frequency of minor infections, slow wound healing, or unusual fatigue as potential signs.

Neglecting to refrigerate reconstituted vials

All three peptides must be refrigerated at 2–8°C after reconstitution. Room temperature storage accelerates degradation. Use within 28–30 days of reconstitution. This applies to BPC-157, KPV, and TB-500 equally.

Frequently Asked Questions

Key Takeaways

The BPC-157 + KPV + TB-500 stack is the most comprehensive anti-inflammation peptide combination — addressing inflammation at molecular (KPV), local (BPC-157), and systemic (TB-500) levels
BPC-157 dose: 250–500 mcg SubQ or oral 1–2x daily for localized tissue repair and gut mucosal healing
KPV dose: 200–500 mcg SubQ or oral daily for NF-κB inhibition and molecular anti-inflammation
TB-500 dose: 2–2.5 mg SubQ twice weekly (loading) then once weekly (maintenance) for systemic healing and cell migration
Use oral BPC-157 and KPV for gut-focused protocols — direct mucosal contact on an empty stomach
Typical cycle: 6–8 weeks, extendable to 12 weeks for chronic inflammatory conditions
Monitor for immunosuppression with prolonged KPV use — take breaks between cycles
Use separate syringes for each injectable peptide — do not mix in the same syringe
Refrigerate reconstituted vials at 2–8°C and use within 28–30 days
None of these peptides are FDA-approved for human use. All are classified as research peptides. Consult a healthcare provider before use.

This article is for educational and informational purposes only. BPC-157, KPV, and TB-500 are not approved by the FDA for human use and are classified as research peptides. They are not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare provider before using any research peptide, especially if you have pre-existing medical conditions, are taking medications, or are pregnant or nursing. See our Medical Disclaimer.

References

Sikiric P, et al. “Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract.” Curr Pharm Des. 2018;24(18):1990-2001.
Brzoska T, et al. “Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo.” Endocr Rev. 2008;29(5):581-602.
Kannengiesser K, et al. “Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.” Inflamm Bowel Dis. 2008;14(3):324-331.
Goldstein AL, et al. “Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues.” Trends Mol Med. 2005;11(9):421-429.
Luger TA, et al. “New insights into the functions of alpha-MSH and related peptides in the immune system.” Ann N Y Acad Sci. 2003;994:133-140.
Seiwerth S, et al. “BPC 157's effect on healing.” J Physiol Paris. 2014;108(2-3):51-59.
Malinda KM, et al. “Thymosin beta4 accelerates wound healing.” J Invest Dermatol. 1999;113(3):364-368.
Getting SJ, et al. “Molecular determinants of the anti-inflammatory actions of the melanocortin peptides.” Pharmacol Ther. 2006;111(1):1-15.
Sikiric P, et al. “Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications.” Curr Neuropharmacol. 2016;14(8):857-865.

Next Steps

Continue your research with these resources.

BPC-157 Dosage Guide

Complete individual dosing protocols, reconstitution, and injection guide for BPC-157.

Read Guide

KPV Dosage Guide

Complete individual dosing protocols, anti-inflammatory mechanisms, and safety for KPV.

Read Guide

TB-500 Dosage Guide

Complete individual dosing protocols, loading/maintenance phases, and safety for TB-500.

Read Guide

Dosage Calculator

Calculate exact doses for all three peptides based on vial size and reconstitution volume.

Open Calculator